Research programme: Ebola virus infections and viral haemorrhagic fever therapeutics- Integrated BioTherapeutics

Drug Profile

Research programme: Ebola virus infections and viral haemorrhagic fever therapeutics- Integrated BioTherapeutics

Alternative Names: CA 45; Filovirus equine immunoglobulin; FVM 04; Pan-Ebola monoclonal antibodies - Integrated BioTherapeutics; Pan-Filovirus monoclonal antibodies - Integrated BioTherapeutics

Latest Information Update: 06 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Integrated BioTherapeutics
  • Developer Auburn University; Emergent BioSolutions; Integrated BioTherapeutics; United States Army Medical Research Institute of Infectious Diseases
  • Class Immunoglobulins; Monoclonal antibodies; Viral vaccines
  • Mechanism of Action Immunoglobulin modulators; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ebola virus infections; Viral haemorrhagic fevers
  • No development reported Marburg virus disease

Most Recent Events

  • 02 Mar 2017 Preclinical development for Ebola virus infections is ongoing USA
  • 15 Nov 2016 Integrated BioTherapeutics and Emergent BioSolutions agree to worldwide co-develop filovirus equine immunoglobulin for haemorrhagic fever from filovirus infection
  • 15 Nov 2016 Early research in Viral haemorrhagic fevers in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top